Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kuppusamy, Gowthamarajan
- Personalized Nano Delivery Strategy in Treating Uveitis
Abstract Views :182 |
PDF Views:0
Authors
Arun Radhakrishnan
1,
Gowthamarajan Kuppusamy
1,
Senthil Venkatachalam
1,
Rohithkrishnan Vijayakumar
1,
Nikhitha K. Shanmukhan
1
Affiliations
1 Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam JSS Academy of Higher Education and Research, IN
1 Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam JSS Academy of Higher Education and Research, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 4 (2019), Pagination: 1997-2008Abstract
Uveitis is an inflammatory disease causes the damage of eye tissues and leads to the loss of vision once kept untreated. Early detection and identification of the disease are necessary for the prevention of the progressing inflammation and tissue damage. Existing treatment comprise of the administration of oral steroids, immunosuppressant, biological and adjuvant therapy. Even though topical, intravitreal and subconjunctival administration routes have been chosen for the drug administration, they fail to achieve the drug concentration to elicit a better therapeutic action due to the presence of ocular barriers such as tear, cornea conjunctiva, sclera, choroid membrane, retina, and blood-retinal barrier. Design of delivery systems that can prolong the precorneal habitation time increase the drug release as well as reduce the side effects such as methods to achieve prolonged can promise effective ocular drug delivery. Delivery systems such as hydrogels, liposomes, micro carrier systems, vitreous implants, medicated lenses, nanotechnology approaches such as nanocrystals, nanoemulsions, nanosuspensions, dendrimers, microneedles etc. exist as current research and the future research perspectives to achieve effective ocular drug delivery.Keywords
Uveitis, Classification, Treatment, Current Status of Therapy, Novel Ocular Drug Delivery.References
- Zhu J, Zhang E, Rio‐Tsonis D. Eye Anatomy. eLS. 2012.
- Al-Dhibi H, Al-Mahmood A, Arevalo J. A. systematic approach to emergencies in uveitis. Middle East African J Ophthalmology, 2014; 21:251-258.
- Nussenblatt R. The natural history of uveitis. International Ophthalmology. 1990; 14:303-308.
- Mustafa M, Muthusamy P, Hussain S. Uveitis: Pathogenesis, Clinical presentations and Treatment. IOSR J Pharmacy (IOSRPHR). 2014; 04:42-47
- Van Laar J, Rothova A, Missotten T. Diagnosis and treatment of uveitis, not restricted to the ophthalmologist.J Clin Transl Res. 2015; 2:94-99
- Lowder C.Y, Char D.H. Uveitis-A review Medical Progress. West J Medicine. 1984; 140:421-432.
- Babu, M., Rathinam, S. Intermediate uveitis. Indian J Ophthalmology. 2010; 58:21-27
- Mustaf M, Muthusamy P, Hussain S.S.Uveitis: Pathogenesis, Clinical presentations and Treatment. IOSR J Pharm., 2014; 4:42-47.
- Biswas J, Sudharshan S, Ganesh S. Current approach in the diagnosis and management of posterior uveitis. Indian J Ophthalmol. 2010; 58:29-43
- Murtaza Mustafa P. MuthusamyS.S, Hussain S.C, Shimmi M.M. Sein. Uveitis: Pathogenesis, Clinical presentations and Treatment. IOSR J of Pharm. 2014; 4:42-47.
- Lin P, Suhler E.B, Rosenbaum J.T. The future of uveitis treatment. Ophthalmol. 2014; 121:365-76.
- Mérida S, Palacios E, Navea A, Bosch-Morell F. New immunosuppressive therapies in uveitis treatment. Int. J. Mol. Sci. 2015; 16:18778-95.
- Horai R, Caspi R.R. Cytokines in autoimmune uveitis. J Interferon Cytokine Res. 2011; 31:733–44.
- Multicenter Uveitis Steroid Treatment Trial Research Group. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010; 149:550-61.
- Ng D, Mohamed S, Chu W.K, Luk F.O, Brelén M, Chan C.K. Update on the management of non-infectious uveitis. Hong Kong Journal of Ophthalmology. 2016; 20:95-105.
- Van Laar J, van Velthoven M, Missotten T, Kuijpers R, van Hagen M, Rothová A. Diagnosis and treatment of uveitis, not restricted to the ophthalmologist. Ned. Tijdschr. Geneeskd. 2013; 157:5703
- Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, Rakus Z, Gottschalk R, Stark S, Brodt H.R, Staszewski S. Comparing Quantiferon-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. Aids. 2008; 22:2471-9.
- Shakarchi F. Ocular tuberculosis: current perspectives. Clin Ophthalmol. 2015; 9:2223-7.
- Gupta V, Al-Dhibi H.A, Arevalo J.F. Retinal imaging in uveitis. Saudi J Ophthalmol 2014; 28:95-103.
- Leder H.A, Campbell J.P, Sepah Y.J, Gan T, Dunn J.P, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, Do DV. Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. Journal of ophthalmic inflammation and infection. 2013; 3:30.
- Babu K, Mahendradas P. Medical Management of Uveitis - Current Trends. Indian J Ophthalmology. 2013; 61:277-283
- John H.K, Altaweel M.M, Holbrook J.T, Multicenter Uveitis Steroid Treatment Trial Research Group. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.Am J Ophthalmol. 2010; 149:550-61.
- Jan A.M, Rothova A, Missotten T, Kuijpers R, van Hagen M, Rothova A. Diagnosis and treatment of uveitis, not restricted to the ophthalmologist. Nederlands tijdschrift voor geneeskunde., 2015; 2:94-99.
- Durrani, O.M., Tehrani, N.N., Marr, J.E., Moradi, P., Stavrou, P., Murray, P.I. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004, 88, 1159-62.
- Sudharshan S, Ganesh S.K, Balu G, Utility of QuantiFERON(R)-TB Gold test in diagnosis and management of suspected tubercular uveitis in India. Int Ophthalmol 2012; 32:217-223.
- Kempen J.H, Van Natta, M.L, Altaweel M.M., Dunn J.P, Jabs D.A, Lightman, S.L, et al. Factors predicting visual acuity outcome in intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment (MUST) trial. Am. J. Ophthalmol. 2015; 160:1133-41.
- Bansal R, Gupta V, Gupta A. Current approach in the diagnosis and management of panuveitis. Indian J Ophthalmol. 2010; 58:45-54.
- Pasadhika S, Suhler E.B, Cunningham, E.T. Biologic therapy for posterior uveitis and panuveitis. Retina today. 2012; 4:74-9.
- Nussenblatt R.B, Peterson J.S, Foster C.S, Rao N.A, See R.F, Letko E, Buggage R.R. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmol., 2005; 112:764-70.
- Mutlukan E. Investigation and management of uveitis. BMJ. 2010; 341.
- Goldhardt R, Rosen B.S. Uveitic macular edema: treatment update. Curr Ophthalmol Rep. 2016; 4:30–37.
- Park Y, Nam H. Clinical features and treatment of ocular toxoplasmosis. Korean J Parasitol. 2013; 51:393-399.
- Gaudana R, Ananthula H.K, Parenky A, Mitra A.K. Ocular drug delivery. The AAPS journal. 2010; 12:348-60.
- Patel A, Cholkar K, Agrahari V, Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World journal of pharmacology. 2013; 47–64.
- Cholkar K, Patel S.P, Vadlapudi A.D, Mitra A.K. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013; 29:106-23.
- He Y, Jia, S.B, Zhang W, Shi J.M. New options for uveitis treatment. International journal of ophthalmology. 2013; 6:702.
- Lin P, Suhler E.B, Rosenbaum J.T. The future of uvetis treatment. Ophthalmology Trans Sci Rev. 2014; 121:365-376.
- Gupta S, Rajesh K.S. Ophthalmic drug delivery systems with emphasis on in-situ hydrogels. Pharmagene, 2013; 1:80-87.
- Ansel H.C, Allen, L.V, Popovich N.G. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 9th ed.Baltimore(MD). Lippincott Williams and Wilkins, 2011.
- Singh K, Harikumar S.L. Injectable in-situ gelling controlled release drug delivery system. Int. j. drug dev. res. 2012; 4:56-69.
- Davies N.M. Biopharmaceutical considerations in topical ocular drug delivery. Clin and exp pharmacol and physiol. 2000; 27:558-562.
- Kuno N, Fujii S. Recent Advances in Ocular Drug Delivery Systems. Polymers. 2011; 3:193-221.
- Dhanapal R, Ratna V.J. Ocular drug delivery system – a review. Int J Innovative Drug Discovery. 2012; 2:4-15.
- Jaffe G, Ben-nun J, Guo H, Dunn J.P, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmol, 2000; 107:2024-33.
- Nussenblatt R, Peterson J, Foster C, Rao N.A, See R.F, Letko E, Buggage R.R. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmol, 2005; 112:764-770.
- Yuan He, Jian-Cheng Wang, Yu-LingLiu, Zhi-Zhong Ma, Xiu-An Zhu, Qiang Zhang. Therapeutic and Toxicological Evaluations of Cyclosporine A Microspheres as a Treatment Vehicle for Uveitis in Rabbits. J Ocul Pharmacol Ther 2006; 22:121-131.
- Higuchi J. W, Higuchi W.I, Li S.K, et al. Noninvasive Delivery of a Transscleral Sustained Release Depot of Triamcinolone Acetonide Using the Visulex Device to Treat Posterior Uveitis. J iovs. 2007, 48, 5822.
- Adibkia K, Omidi Y, Siahi M.R, Javadzadeh A.R., Barzegar-Jalali, M., Barar, J., Maleki, N., Mohammadi G, Nokhodchi, A. Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther, 2007; 23:421-32.
- Barcia E, Herrero-Vanrell R., Diez A., Alvarez-Santiago C, Lopez 1, Calonge, M, Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp Eye Res. 2009; 89: 238—245.
- Lajavardi L, Camelo S, Agnely F, et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Controlled Release 2009; 139:22-30.
- Shen J, Gan L, Zhu C, et al. Novel NSAIDs ophthalmic formulation: Flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. International Journal of Pharmaceutics. 2011; 412:115-122.
- Kilmartin D, Forrester J, Dick A, Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br. J. Ophthalmol. 1998; 82:737-742.
- Harikumar S.L, Sonia A. Nanotechnological approaches in Ophthalmic delivery systems. Int J Drug Dev & Res. 2011; 3:9-19.
- Webb, P.A, Orr, C. Analytical Methods in Fine Particle Technology, Micromeritics Instrument Corp. Norcros. Stud in Surf Sci and Catal1997; 273–280.
- Amrite A.C, Kompella U.B. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005; 57:1555-1563.
- Sukari E and Flora D. The effect of Particle Size of Polymeric Nanospheres on Intraviteral Kinetics. Opthalomol Resear. 2001; 33:31-36.
- Donnelly R.F, Raj Singh T.R, Woolfson A.D. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv 2010; 17:187–207.
- Lee S.S, Hughes P, Ross A.D, Robinson M.R. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010; 27:2043–2053.
- Patton T.F, Robinson J.R. Ocular Evaluation of Polyvinyl alchol vechile in rabbits. J. A. pharm.Sci.1975; 64:1312-1316.
- Hathout R.M, Mansour S, Mortada N.D, Guinedi A.S. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2007; 5:1.
- Mandal A, Bisht R, Rupenthal I.D, Mitra A.K. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.J. Control. Release. 2017; 248:96-116.
- Milhe O.M, Myles C, Yamakawa J, McKeown N.B, Attwood D, D’Emanuele A. Polyamidoamine Starburst® dendrimers as solubility enhancers. International journal of pharmaceutics. 2000; 197:239-41.
- Rajoria G, Gupta A. In-situ gelling system: a novel approach for ocular drug delivery. Am J Pharm Tech Res 2012; 2:24-53.
- Indu P.K, Manjit S, Meenakshi K. Formulation and Evaluation of Ophthalmic Preparations of Acetazolamide.Int J Pharm 2000; 199:119-127.
- Simvastatin Loaded Polycaprolactone-Collagen Scaffolds for the treatment of Diabetic Foot Ulcer
Abstract Views :216 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, JSS College of Pharmacy, Ooty, IN
1 Department of Pharmaceutics, JSS College of Pharmacy, Ooty, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 6 (2019), Pagination: 2637-2644Abstract
Scaffolds are the adaptable tools for the treatment of diabetic wounds, In this study, Simvastatin was loaded in polycaprolactone-collagen scaffolds for the treatment of diabetic foot ulcer using the freeze-drying technique. Eventually scaffolds characterization were observed in terms of Scanning Electron Microscopy, Differential scanning calorimetry (DSC), Porosity, Water absorption test, Matrix degradation, In vitro drug release studies, cell proliferation assay, cytotoxicity assay. Scaffolds prepared with polycaprolactone and collagen-polymer showed the homogeneous distribution with high porosity, extended biodegradation rate, high water uptake. All the scaffold formulation showed the sustained drug release and then a plateau. The cross-Linked scaffold has significant slower release in comparison to non-crosslinked scaffold, this is because of cross-linking of the scaffolds where the chemical and mechanical bonding is high compared to non-crosslinked scaffold, Non-crosslinked, showed 85.34% of drug release by this it can be concluded that non cross-linked scaffolds showed the prolonged release, In the cell proliferation assay after 72 h, the cell growth was found to be greater when we compared with placebo and control due to the presence of drug, which explains that the cells are in logarithmic phase. Noncross linked scaffold has shown an increase in cell growth by 28% from its initial value. In Differential Scanning Calorimetry (DSC) shows that there is no change in the peaks by that we can confirm that all the excipients are compatible to each other The obtained results imply that the investigated scaffold is a potential candidate for skin regeneration application because the present study states that simvastatin is having all the properties to treat the Diabetic Foot Ulcer(DFU) without producing the resistance.Keywords
Simvastatin, Polycaprolactone, Collagen, Composite Scaffolds, Diabetic Wounds.References
- Karri VVSR, Kuppusamy G, Talluri SV, Yamjala K, Mannemala SS, Malayandi R. Current and emerging therapies in the management of diabetic foot ulcers. Curr Med Res Opin [Internet]. 2016;32(3):519–42. Available from: http://www.tandfonline.com/doi/full/10.1185/03007995.2015.1128888
- Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci. 2016;73(20):3861–85.
- Mahmoud AA, Salama AH. Norfloxacin-loaded collagen/chitosan scaffolds for skin reconstruction: Preparation, evaluation and in-vivo wound healing assessment. Eur J Pharm Sci [Internet]. 2016; 83:155–65. Available from: http://dx.doi.org/10.1016/j.ejps.2015.12.026
- Mir M, Najabat M, Afifa A, Ayesha B, Munam G, Shizza A. Synthetic polymeric biomaterials for wound healing: a review. Prog Biomater [Internet]. 2018; (Mostow 1994). Available from: https://doi.org/10.1007/s40204-018-0083-4
- Cínthia A, Irami R, Filho A, Damasceno BPGL, Sócrates E, Egito T. Simvastatin improves the healing of infected skin wounds of rats 1 A Simvastatina melhora a cicatrização de feridas infectadas da pele de ratos. 2007;22(Supplement 1):57–63.
- Farsaei S, Khalili H, Farboud ES. Potential role of statins on wound healing: review of the literature. 2012;238–47.
- Baxter R, Hastings N, Law a., Glass EJ. [ No Title]. Anim Genet. 2008;39(5):561–3.
- Thangavel P, Ramachandran B, Muthuvijayan V. Fabrication of chitosan / gallic acid 3D microporous scaffold for tissue engineering applications. 2015;750–60.
- Sultana N, Khan TH. Water absorption and diffusion characteristics of nanohydroxyapatite (nHA) and poly(hydroxybutyrate-co-hydroxyvalerate-) based composite tissue engineering scaffolds and nonporous thin films. J Nanomater. 2013;2013.
- Kumar PTS, Srinivasan S, Lakshmanan V, Tamura H, Nair S V, Jayakumar R.  -Chitin hydrogel / nano hydroxyapatite composite scaffolds for tissue engineering applications. Carbohydr Polym [Internet]. 2011;85(3):584–91. Available from: http://dx.doi.org/10.1016/j. carbpol.2011.03.018
- Sun X, Wang J, Wang Y, Zhang Q. Collagen-based porous scaffolds containing PLGA microspheres for controlled kartogenin release in cartilage tissue engineering. Artif Cells, Nanomedicine, Biotechnol [Internet]. 2017;0(0):1–10. Available from: https://doi.org/10.1080/21691401.2017.1397000
- Vernon RB, Gooden MD, Lara SL, Wight TN. Microgrooved fibrillar collagen membranes as scaffolds for cell support and alignment. 2005; 26:3131–40.
- Demirci S, Doğan A, Demirci Y, Şahin F. In vitro wound healing activity of methanol extract of Verbascum speciosum. 2014;7(3):37–44.
- Saurabh Mehta. Review of Heterocyclic Scaffolds for the Inhibitors of ATP synthase. Asian J. Research Chem. 2018; 11(2):505-508.
- Radhika G, Sreelakshmi Divya P, Prashanth Reddy G, Venkatesh P, Ravindra Reddy K. An Overview on Regenerative Medicine. Research J. Pharm. and Tech.3 (3): July-Sept. 2010; Page 727-728.
- Hisham A. Abbas. Diabetic Foot Infection. Research J. Pharm. and Tech. 8(5): May, 2015; Page 575-579.
- P. Maheshwari, D. Pavithra, Neethu. T. T, T.S. Shanmugarajan, P. Shanmugasundaram. Study on Health Outcomes in Diabetic Patients - Association Between Diabetic Foot Ulcer and Psychological Distress. Research J. Pharm. and Tech. 2017; 10(1): 44-48.
- Radhika Chelamalla, Ajitha Makula. Molecular docking studies and ADMET Predictions of Pyrimidine Coumarin Scaffolds as Potential IDO Inhibitors. Asian J. Research Chem. 2017; 10(3):331-340.
- Bonshikachatterjee, Nivetha. A, Mohanasrinivasan. V. Immobilization of β-galactosidase in Chitosan-Alginate composite scaffolds and optimization of lactose hydrolysis. Research J. Pharm. and Tech 2018; 11(4): 1480-1485.
- Smriti Agarwal, Vinayak Jhunjhunwala, G. Priya. Fabrication and Morphological Analysis of Gelatin-Alginate Scaffolds. Research J. Pharm. and Tech 2018; 11(9): 3816-3818.
- Saumya S, Agila Anbuselvan, Poorva S, G. Priya. A Review on 3D Printing Techniques and Scaffolds for Auricular Cartilage Reconstruction. Research J. Pharm. and Tech 2018; 11(9): 4179-4186
- Keerthic Aswin S, Jothishwar S, Visvavela Chellaih Nayagam P, G. Priya. Scaffolds for Biomolecule Delivery and Controlled Release–A Review. Research J. Pharm. and Tech 2018; 11(10): 4719-4730.
- Hisham A. Abbas, Mona A. El-Sayed, Laila M. Al-Kadi, Amany I. Gad. Diabetic foot infections in Zagazig University Hospital: bacterial etiology, antimicrobial resistance and biofilm formation. Research J. Pharm. and Tech. 7(7): July 2014 Page 783-788
- P. Maheshwari, D. Pavithra, Neethu. T. T, T.S. Shanmugarajan, P. Shanmugasundaram. Study on Health Outcomes in Diabetic Patients - Association Between Diabetic Foot Ulcer and Psychological Distress. Research J. Pharm. and Tech. 2017; 10(1): 44-48.
- Robson MC, Mustoe TA, Hunt TK. The future recombinant growth factors in wound healing. Am J Surg 1998;2(suppl 1):80-2S